NCT01067235View on ClinicalTrials.gov

Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
NarcolepsyCataplexyExcessive Daytime Sleepiness
Interventions
DRUG

BF2.649

BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks

DRUG

BF2.649 add on Modafinil

BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks

Trial Locations (1)

6903

Neurocenter (EOC) of Southern Switzerland, Lugano

Sponsors

Lead Sponsor

Bioprojet
All Listed Sponsors
lead

Bioprojet

OTHER